Issue 17, 2025

Decoding the selective mechanism behind a monobody inhibitor to the phosphatase domain of SHP2: insights from molecular dynamics simulations

Abstract

The Src-homology 2 (SH2) domain-containing phosphatase 2 (SHP2), encoded by PTPN11, is a critical tyrosine phosphatase that regulates key cellular processes, including cell proliferation, survival, and migration. The catalytic activity of its protein tyrosine phosphatase (PTP) domain plays a pivotal role in cancer progression by activating oncogenic signaling pathways. In contrast, SHP1, another SH2 phosphatase encoded by PTPN6, generally functions as a tumor suppressor. Given their structural similarity yet distinct biological functions, developing selective SHP2-PTP inhibitors is crucial for targeted cancer therapy. Recently, a monobody, Mb (SHP2PTP_13) (Mb13), has been designed to bind to the SHP2-PTP structure specifically. However, the detailed mechanism involved in selective inhibition remains to be clarified. To achieve this objective, we conducted extensive molecular dynamics simulations of the Mb13–SHP2-PTP and Mb13–SHP1-PTP systems, together with multiple analyses, including cluster analysis, principal component analysis, free energy landscape evaluation, a cross-correlation matrix and binding free energy calculation. Our results demonstrated that Mb13 bound more stably to SHP2-PTP compared to SHP1-PTP. The SHP2 complex exhibited conformational stability and reduced flexibility, indicating a more substantial interaction. Detailed analysis revealed that key residues within SHP2-PTP formed more robust interactions with Mb13, enhancing the complex's overall stability. These findings suggested that the selective binding mechanism was primarily driven by specific stabilizing interactions at the molecular level. Overall, the enhanced understanding of SHP2-PTP's binding dynamics and stability offers valuable guidance for advancing drug design strategies targeting SHP2-mediated pathways.

Graphical abstract: Decoding the selective mechanism behind a monobody inhibitor to the phosphatase domain of SHP2: insights from molecular dynamics simulations

Supplementary files

Article information

Article type
Paper
Submitted
16 Jan 2025
Accepted
31 Mar 2025
First published
03 Apr 2025

Phys. Chem. Chem. Phys., 2025,27, 9132-9142

Decoding the selective mechanism behind a monobody inhibitor to the phosphatase domain of SHP2: insights from molecular dynamics simulations

Y. Wang, M. Ji, L. Zhou, Q. Zhang, X. Lu, N. Liu, X. Li and S. Lu, Phys. Chem. Chem. Phys., 2025, 27, 9132 DOI: 10.1039/D5CP00211G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements